Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential buyout for AZN.
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.